Literature DB >> 2578012

Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors.

P Carde1, J M Burgers, M Henry-Amar, M Hayat, W Sizoo, E Van der Schueren, M Monconduit, E M Noordijk, J Lustman-Marechal, A Tanguy.   

Abstract

The H5 program in clinical stage (CS) I to II supradiaphragmatic Hodgkin's disease (HD) was tailored to prognostic factors identified in former European Organization for the Research and Treatment of Cancer (EORTC) studies. Among the 494 adult patients included in the study, the 237 patients belonging to the favorable group (H5F) underwent a staging laparotomy (Sx) in order to select the patients who could be treated with limited radiotherapy (RT) only. Thus, 198 patients (84%) with negative laparotomy were treated with RT alone and randomized to either mantle irradiation (M) or extended field mantle plus para-aortic (M + PA) irradiation. Complete remission (CR) was achieved in 99% of the patients. There was no difference in the 6-year relapse-free survival (RFS) rate (74% and 72%, respectively) or survival rate (96% and 89%). Therefore, Sx helped to define those patients who could be treated with M alone in contrast to those who required more aggressive therapy. The 39 patients with positive laparotomy were treated as the unfavorable group (H5U) from onset and randomized to either total/subtotal nodal irradiation (TNI/STNI) or a sandwiched mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) X 3, M irradiation, MOPP X 3 protocol (3M). Although the RFS rate was higher in the 3M arm (100% v 53%; P = .002), the 6-year survival was not significantly different between the two arms (overall, 92%). In the 257 patients with initial unfavorable disease, the Sx was avoided. They were randomized to either TNI/STNI or 3M. In complete responders (96%), the 6-year RFS was 91% in the 3M arm and 77% in the TNI/STNI arm (P = .02). The pattern of failure differed in the two arms: the inverted Y and spleen irradiation controlled occult infradiaphragmatic disease better than MOPP; conversely, less patients begun on MOPP recurred in the involved mantle areas. The difference in 6-year actuarial total survival (TS) (89% and 82%; P = .05 in favor of the 3M arm) was not retrieved after exclusion of the unrelated deaths from the analysis. The two arms produced similar TS in patients under 40 years of age. TNI retains interest, especially in young men wishing to preserve fertility. The overall result shows that when treatment is tailored to initial prognostic factors, excellent results can be obtained in all patient subgroups at minimal morbidity and toxic cost.

Entities:  

Mesh:

Year:  1988        PMID: 2578012     DOI: 10.1200/JCO.1988.6.2.239

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  14 in total

Review 1.  Early-stage Hodgkin's disease.

Authors:  A Josting; V Diehl
Journal:  Curr Oncol Rep       Date:  2001-05       Impact factor: 5.075

2.  Restaging with gallium scan identifies chemosensitive patients and predicts survival of poor-prognosis mediastinal Hodgkin's disease patients.

Authors:  I Ionescu; P Brice; D Simon; A Guermazi; T Leblanc; P Rousselot; D Gossot; V Meignin; C Gisselbrecht; J D Rain
Journal:  Med Oncol       Date:  2000-05       Impact factor: 3.064

3.  ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.

Authors:  Ralph M Meyer; Mary K Gospodarowicz; Joseph M Connors; Robert G Pearcey; Woodrow A Wells; Jane N Winter; Sandra J Horning; A Rashid Dar; Chaim Shustik; Douglas A Stewart; Michael Crump; Marina S Djurfeldt; Bingshu E Chen; Lois E Shepherd
Journal:  N Engl J Med       Date:  2011-12-11       Impact factor: 91.245

Review 4.  Hodgkin's lymphoma. II: Treatment and delayed morbidity.

Authors:  P Carde
Journal:  BMJ       Date:  1992-07-18

Review 5.  Hodgkin's disease--I: Identification and classification.

Authors:  P Carde
Journal:  BMJ       Date:  1992-07-11

Review 6.  Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy.

Authors:  Ralph M Meyer; Richard T Hoppe
Journal:  Blood       Date:  2012-07-20       Impact factor: 22.113

Review 7.  Balancing risks and benefits of therapy for patients with favorable-risk limited-stage Hodgkin lymphoma: the role of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy alone.

Authors:  Annette E Hay; Ralph M Meyer
Journal:  Hematol Oncol Clin North Am       Date:  2014-02       Impact factor: 3.722

8.  Current treatment strategies in early stage Hodgkin's disease.

Authors:  Andreas Josting; Volker Diehl
Journal:  Curr Treat Options Oncol       Date:  2003-08

9.  Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines.

Authors:  Frederika A van Nimwegen; Georgios Ntentas; Sarah C Darby; Michael Schaapveld; Michael Hauptmann; Pieternella J Lugtenburg; Cecile P M Janus; Laurien Daniels; Flora E van Leeuwen; David J Cutter; Berthe M P Aleman
Journal:  Blood       Date:  2017-01-31       Impact factor: 22.113

Review 10.  New treatments for Hodgkin's disease.

Authors:  Jan-Peter Glossmann; Andreas Josting; Volker Diehl
Journal:  Curr Treat Options Oncol       Date:  2002-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.